Lindus Therapeutics welcomed Dr. Gillian Cannon as a non-executive director.

Lindus Therapeutics is a next-generation drug development company. We advance portfolios of in-licensed assets, pairing our asset identification and selection capability with an integrated clinical trial delivery platform. Domain experts work hand in glove with proprietary AI systems that enable us and our partners to reach value inflection points faster and more efficiently than the industry standard. Lindus is backed by investors and advisors including Peter Thiel and Bob Langer.